ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia

Phase 3

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: FK199B
Drug: Zolpidem

First Posted Date: 2009-10-21

Last Posted Date: 2014-08-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 55

Registration Number: NCT00999219

Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients

Completed

Conditions: Urinary Bladder, Overactive
Overactive Bladder

Interventions: Drug: Solifenacin

First Posted Date: 2009-09-28

Last Posted Date: 2011-10-12

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1215

Registration Number: NCT00985387

Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ASP1517
Drug: Placebo

First Posted Date: 2009-09-16

Last Posted Date: 2010-06-22

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 100

Registration Number: NCT00978198

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer
Pharmacokinetics of YM178

Interventions: Drug: YM178

First Posted Date: 2009-08-26

Last Posted Date: 2013-07-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 72

Registration Number: NCT00965926

A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

Phase 1

Completed

Conditions: Osteoporosis
Osteoporosis, Postmenopausal
Bone Diseases

Interventions: Drug: ONO-5920 / YM529

First Posted Date: 2009-08-26

Last Posted Date: 2009-10-05

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 48

Registration Number: NCT00965978

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Phase 3

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: YM178
Drug: Placebo
Drug: tolterodine

First Posted Date: 2009-08-26

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1139

Registration Number: NCT00966004

A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients

Phase 4

Completed

Conditions: Sleep Initiation and Maintenance Disorders
Primary Insomnia

Interventions: Drug: Zolpidem MR
Drug: Estazolam

First Posted Date: 2009-08-11

Last Posted Date: 2011-10-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 42

Registration Number: NCT00956319

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: YM150
Procedure: mechanical prophylaxis

First Posted Date: 2009-07-20

Last Posted Date: 2010-06-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 156

Registration Number: NCT00942435

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of Mirabegron

Interventions: Drug: mirabegron

First Posted Date: 2009-07-15

Last Posted Date: 2013-06-26

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 76

Registration Number: NCT00939757

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of Mirabegron

Interventions: Drug: mirabegron

First Posted Date: 2009-07-15

Last Posted Date: 2024-10-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 91

Registration Number: NCT00940121

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy